



March 17, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Symbol: STAR

Dear Madam/ Sirs,

Sub: Disclosure under Regulation 30 of SEBI Listing Regulations

This has reference to the press release issued by the Company today titled “**Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz**”.

In this regard, please find enclosed herewith disclosure under Regulation 30 of SEBI Listing Regulations.

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No. A30515

Encl. as above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000
Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com

**Disclosure under Regulation 30 of SEBI Listing Regulations
read with SEBI Master Circular dated January 30, 2026**

Details relating to acquisition of Multiple Generic Brands from Sandoz

#	Particulars	Remarks
1	Name of the entities with whom agreement is signed	<p>Parties to the agreement are:</p> <p>Strides Pharma International AG, Switzerland (SPIAG), a step-down subsidiary of the Company</p> <p>Sandoz AG, Switzerland and its group entities (collectively referred to as “Sandoz”)</p> <p>Strides Pharma Global Pte. Limited, Singapore (SPG), a step-down wholly owned subsidiary of the Company, as Corporate Guarantor on behalf of SPIAG.</p>
2	Area of Agreement Domestic/ International	SPIAG has executed definitive agreements with Sandoz for acquisition and in-licensing of certain branded generic products across the Sub-Saharan Africa (SSA) region.
3	Scope of Business Operations of the Agreement Rationale and benefit expected	<p>The transaction covers four key markets—Western Sahara, Ghana, Nigeria, and Kenya—where Strides has an established operating presence.</p> <p>The integration of Strides’ existing operations with the Sandoz portfolio is expected to position Strides among the top five pharmaceutical companies in the SSA region by sales, and among the top two within its represented markets.</p> <p>The portfolio comprises multiple established brands across the anti-infective, cardiovascular, and dermatology segments.</p> <p>Several of these products individually record annual sales exceeding USD One Million, significantly bolstering the existing business meaningfully.</p>
4	Share Exchange Ratio	Not applicable

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com

#	Particulars	Remarks
5	Details of Consideration	<p>The upfront consideration for the proposed transaction is USD 12 Million, payable at closing.</p> <p>The transaction also provides for royalty payments to Sandoz based on a percentage of net sales of Distribution Products.</p> <p>The transaction is subject to customary closing conditions, including antitrust filings in one or more jurisdictions, as may be required.</p> <p>As part of the transaction, Strides Pharma Global Pte. Limited, Singapore (SPG), a step-down wholly owned subsidiary of the Company and Holding Company of SPIAG, shall provide a guarantee to Sandoz to secure the payment obligations of SPIAG, as under:</p> <ul style="list-style-type: none"> • A guarantee securing the upfront payment of USD 12 million, which will remain valid until closing and will be released upon completion of payment by SPIAG. • A guarantee to secure the payment of yearly royalty on Distribution Products, the amount of which is variable and linked to sales performance during each year.
6	Significant Terms & Conditions of the Agreement	<p>The portfolio being transacted includes brands that are being fully acquired by Strides, as well as certain brands that Strides is in-licensing from Sandoz.</p> <p>The arrangement also provides for yearly royalty payments to the Sandoz based on a percentage of net sales for the Distribution Products.</p> <p>The said transaction is expected to achieve closure by end of Q2 FY 27 (Quarter Ending 30th September 2026).</p>

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com

#	Particulars	Remarks
7	<p>Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at “arm’s length.</p>	<p>The said transaction with Sandoz is not a Related Party Transaction.</p> <p>Transaction between SPIAG and SPG are inter-company transactions and are considered as Related Party Transactions. And these RPT are at arms’ length.</p> <p>Promoter/ Promoter Group of Strides do not have any interest in the said transactions.</p>
8	Size of entities	Not applicable for the said transaction with Sandoz.

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com

**Disclosure under Regulation 30 of SEBI Listing Regulations
read with SEBI Master Circular dated January 30, 2026**

**Details related to Corporate Guarantee provided by Strides Pharma Global Pte. Limited,
Singapore, a step-down wholly owned subsidiary of the Company**

#	Particulars	Remarks
1	Name of party for which such guarantee/ indemnity/ surety was given.	Strides Pharma Global Pte. Limited, Singapore (SPG) , a step-down wholly owned subsidiary of the Company, has provided Corporate Guarantor to Sandoz AG, Switzerland and its group entities (collectively referred to as “Sandoz”) on behalf of Strides Pharma International AG, Switzerland (SPIAG) , a step-down subsidiary of the Company
2	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at “arm’s length	The said transaction with Sandoz is not a Related Party Transaction. Transaction between SPIAG and SPG are inter-company transactions and are considered as Related Party Transactions. And these RPT are at arms’ length. Promoter/ Promoter Group of Strides do not have any interest in the said transactions.
3	Brief details of such guarantee viz. <ul style="list-style-type: none"> • Brief details of agreement entered, if any • Significant terms and conditions • Amount of guarantee 	SPIAG has executed definitive agreements with Sandoz for the acquisition and in-licensing of certain branded generic products across the Sub-Saharan Africa (SSA) region. As part of the transaction, Strides Pharma Global Pte. Limited, Singapore (SPG), a step-down wholly owned subsidiary of the Company and Holding Company of SPIAG, shall provide a guarantee to Sandoz to secure the payment obligations of SPIAG, as follows: <ul style="list-style-type: none"> • A guarantee securing the upfront payment of USD 12 million, which will remain valid until closing and will be released upon completion of payment. • A guarantee to secure the payment of yearly royalty on Distribution Products, the amount of which is variable and linked to sales performance during each year.

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com



#	Particulars	Remarks
4	Impact of Corporate Guarantee on the Listed Entity/ Guarantor	<p>The said guarantee shall be recognized as a contingent liability in the books of SPG.</p> <p>There is no material financial impact arising from the said guarantee in the books of Strides Pharma Science Limited, India, the listed entity.</p>

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com